Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.905
-0.015 (-0.30%)
At close: Apr 28, 2026, 4:00 PM EDT
4.905
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 33 employees as of December 31, 2025. The number of employees decreased by 4 or -10.81% compared to the previous year.
Employees
33
Change (1Y)
-4
Growth (1Y)
-10.81%
Revenue / Employee
n/a
Profits / Employee
-$786,879
Market Cap
5.80M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| PMGC Holdings | 34 |
| Cardio Diagnostics Holdings | 17 |
| BioRestorative Therapies | 14 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Ernexa Therapeutics | 7 |
| Mustang Bio | 4 |
APVO News
- 4 weeks ago - Aptevo Provides State of the Business Report and 2025 Financial Results - Accesswire
- 5 weeks ago - Aptevo to Participate in March 2026 Conferences - Accesswire
- 7 weeks ago - Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Accesswire
- 3 months ago - Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth - Accesswire
- 3 months ago - Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality - Accesswire
- 4 months ago - Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - Accesswire
- 5 months ago - Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - Accesswire
- 6 months ago - Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Accesswire